Holen Sie sich die Stockscreener-App
4.44
0.22%
-0.010
Handel nachbörslich:
4.75
0.31
+6.98%
Schlusskurs vom Vortag:
$4.45
Offen:
$4.52
24-Stunden-Volumen:
451.12K
Relative Volume:
1.02
Marktkapitalisierung:
$274.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-1.9821
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
+1.95%
1M Leistung:
-13.95%
6M Leistung:
-33.93%
1J Leistung:
-7.88%
1-Tages-Spanne:
$4.415
$4.66
1-Wochen-Bereich:
$4.12
$4.66
52-Wochen-Spanne:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.44 | 258.77M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Tick level data insight on Monte Rosa Therapeutics Inc. volatilityEarnings Performance Report & Reliable Breakout Forecasts - Newser
Is Monte Rosa Therapeutics Inc. stock ready for a breakoutMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Should you wait for a breakout in Monte Rosa Therapeutics Inc.Weekly Profit Analysis & Expert Curated Trade Setup Alerts - Newser
Applying big data sentiment scoring on Monte Rosa Therapeutics Inc.Profit Target & Fast Moving Trade Plans - Newser
Can machine learning forecast Monte Rosa Therapeutics Inc. recoveryStrong Buy Opportunity with Volume Support - Newser
Leading vs lagging indicators on Monte Rosa Therapeutics Inc. performanceStock Holding Strategy Long-Term Summary Sheet - Newser
Statistical indicators supporting Monte Rosa Therapeutics Inc.’s strengthShort-Term Trade Setup with Forecast Insight - Newser
How Monte Rosa Therapeutics Inc. stock performs during market volatilityAlpha Stock Picks with Chart Confirmation - Newser
Should you hold or exit Monte Rosa Therapeutics Inc. nowPredictable Entry Strategy With Technical Backing - Newser
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attentionWeekly Portfolio Update with ROI Focus - Newser
How to recover losses in Monte Rosa Therapeutics Inc. stockAI Generated Momentum Stock Forecast Guide - Newser
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Monte Rosa Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Monte Rosa Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Monte Rosa Therapeutics Reports Q2 2025 Earnings - TipRanks
Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Growth Potential - TipRanks
Monte Rosa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Monte Rosa Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Monte Rosa (GLUE) Q2 Revenue Jumps 394% - The Globe and Mail
Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M - TipRanks
Monte Rosa Therapeutics, Inc. SEC 10-Q Report - TradingView
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Monte Rosa Earnings: 3 Clinical Programs Progress as Cash Runway Extends to 2028, Revenue Jumps 393% - Stock Titan
Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday - Defense World
How institutional ownership impacts Monte Rosa Therapeutics Inc. stockEarly Entry Ideas with Momentum Potential - Newser
What are Monte Rosa Therapeutics Inc. company’s key revenue driversAchieve breakthrough gains with smart trades - Jammu Links News
Should I hold or sell Monte Rosa Therapeutics Inc. stock in 2025Achieve breakthrough investment performance - Jammu Links News
How does Monte Rosa Therapeutics Inc. generate profit in a changing economySky-high return potential - Jammu Links News
What institutional investors are buying Monte Rosa Therapeutics Inc. stockConsistent wealth multiplication - Jammu Links News
How strong is Monte Rosa Therapeutics Inc. company’s balance sheetMaximize your portfolio’s growth potential - Jammu Links News
Does Monte Rosa Therapeutics Inc. stock perform well during market downturnsHigh-octane gains - Jammu Links News
What drives Monte Rosa Therapeutics Inc. stock priceOutstanding capital appreciation - Jammu Links News
What catalysts could drive Monte Rosa Therapeutics Inc. stock higher in 2025Unlock daily market insights for better trades - Jammu Links News
How does Monte Rosa Therapeutics Inc. compare to its industry peersFree High-Return Strategy Alerts - Jammu Links News
Options Data Show Bullish Bias in Monte Rosa Therapeutics Inc.Pattern Detection for Entry Confirmation Enabled - metal.it
Sector ETF performance correlation with Monte Rosa Therapeutics Inc.Price Movement and Market Sentiment Analysis - Newser
GLUE’s Stock Market Adventure: 19.49% YTD Growth Amidst Volatility - investchronicle.com
Will Monte Rosa Therapeutics Inc. bounce back from current supportFree Chart Breakout Buy Signal Detection - Newser
How to integrate Monte Rosa Therapeutics Inc. into portfolio analysis toolsEarnings Based Stock Performance Forecast - Newser
What makes Monte Rosa Therapeutics Inc. stock price move sharplyLow Risk High Return Opportunities Identified - metal.it
Real time scanner hits for Monte Rosa Therapeutics Inc. explainedBuy Signal System Based on Price Action - Newser
Monte Rosa Therapeutics Inc. Rebound Backed by Sentiment Shift - metal.it
Can Monte Rosa Therapeutics Inc. Regain Lost Ground This QuarterLow Risk High Return Opportunities Identified - metal.it
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):